Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Saved in:
| Title: | Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals |
|---|---|
| Authors: | Christoph D. Spinner, Samira Bell, Hermann Einsele, Cécile Tremblay, Michel Goldman, Zain Chagla, Axel Finckh, Christopher J. Edwards, Igor Aurer, Odile Launay, Carolina Casañas i Comabella, Samantha James, Sabada Dube, Katarzyna Borkowska, Fungwe Jah, Walid Kandeil, Renata T. C. Yokota, Cécile Artaud, Jacques-Eric Gottenberg, Loreto Gesualdo, Dominique Bertrand, Sofie Arnetorp, Gkikas Magiorkinis |
| Source: | Adv Ther |
| Publisher Information: | Springer Science and Business Media LLC, 2024. |
| Publication Year: | 2024 |
| Subject Terms: | COVID-19 Vaccines, SARS-CoV-2, COVID-19 / therapy, COVID-19 / psychology, Review, ddc, COVID-19 / epidemiology, Immunocompromised Host, Cost of Illness, COVID-19, Immunocompromised, Mental health, Economic burden, Health-related quality of life, Humanistic burden, COVID-19 / immunology, Quality of Life, Humans, COVID-19 / economics |
| Description: | Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, individuals with immunocompromising conditions continue to face challenges given their suboptimal response to vaccination and vulnerability to severe COVID-19. This expert review synthesizes recent published evidence regarding the economic and human impact of COVID-19 on such individuals. The literature suggests that rates of hospitalization, intensive care unit admission, and mechanical ventilation use were high during the pre-Omicron era, and remained high during Omicron and later, despite vaccination for this population. Moreover, studies indicated that these individuals experienced a negative impact on their mental health and health-related quality of life (HRQoL) compared to those without immunocompromising conditions, with elevated levels of anxiety, depression, and distress reported. Further, these individuals with immunocompromising conditions experienced substantial costs associated with COVID-19 and loss of income during the pandemic, though the evidence on the economic burden of COVID-19 in such individuals is limited. Generally, COVID-19 has increased healthcare resource use and costs, impaired mental health, and reduced HRQoL in those with varied immunocompromising conditions compared to both those without COVID-19 and the general population-underscoring the importance of continued real-world studies. Ongoing research is crucial to assess the ongoing burden of COVID-19 in vaccinated individuals with immunocompromising conditions who are still at risk of severe COVID-19 outcomes to ensure their needs are not disproportionately worse than the general population. |
| Document Type: | Article Other literature type Review |
| File Description: | application/pdf |
| Language: | English |
| ISSN: | 1865-8652 0741-238X |
| DOI: | 10.1007/s12325-024-03043-0 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/39680311 https://pergamos.lib.uoa.gr/uoa/dl/object/3498725 https://urn.nsk.hr/urn:nbn:hr:105:287212 https://doi.org/10.1007/s12325-024-03043-0 https://mediatum.ub.tum.de/1774123 |
| Rights: | CC BY NC URL: http://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) . |
| Accession Number: | edsair.doi.dedup.....d6570c24dc6a0528c620189ef7c0c4be |
| Database: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, individuals with immunocompromising conditions continue to face challenges given their suboptimal response to vaccination and vulnerability to severe COVID-19. This expert review synthesizes recent published evidence regarding the economic and human impact of COVID-19 on such individuals. The literature suggests that rates of hospitalization, intensive care unit admission, and mechanical ventilation use were high during the pre-Omicron era, and remained high during Omicron and later, despite vaccination for this population. Moreover, studies indicated that these individuals experienced a negative impact on their mental health and health-related quality of life (HRQoL) compared to those without immunocompromising conditions, with elevated levels of anxiety, depression, and distress reported. Further, these individuals with immunocompromising conditions experienced substantial costs associated with COVID-19 and loss of income during the pandemic, though the evidence on the economic burden of COVID-19 in such individuals is limited. Generally, COVID-19 has increased healthcare resource use and costs, impaired mental health, and reduced HRQoL in those with varied immunocompromising conditions compared to both those without COVID-19 and the general population-underscoring the importance of continued real-world studies. Ongoing research is crucial to assess the ongoing burden of COVID-19 in vaccinated individuals with immunocompromising conditions who are still at risk of severe COVID-19 outcomes to ensure their needs are not disproportionately worse than the general population. |
|---|---|
| ISSN: | 18658652 0741238X |
| DOI: | 10.1007/s12325-024-03043-0 |